Diasorin S.p.a. · MIL:DIA
Diasorin — Q2 2025 Earnings Presentation
18 slides from Diasorin's earnings presentation, Jul 31, 2025
Slide 1: Q2 and H1 2025 Results
Q2 AND H1 2025 RESULTS July 31, 2025
Slide 2: Disclaimer
DISCLAIMER In General. This disclaimer applies to this presentation and any oral No distribution of this Presentation. This Presentation is being furnished to you comments of any person presenting it. This document, taken together with solely for your information and may not be reproduced, in whole
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 5: Financial Highlights
FINANCIAL HIGHLIGHTS Change Change Amounts in €/mln H1 2025 Q2 2025 @ current @ CER @ current @ CER Revenues 619 +5% +6% 306 +2% +5% Immunodiagnostics ex-COVID 418 +7% +8% 215 +5% +8% Molecular Diagnostics ex-COVID 103 +3% +4% 47 -5% +1% Licensed Technologies 91 +9% +10% 42 +1% +7% COVID 7 -50% -49%
Slide 6: H1 2025 Key Facts
H1 2025 KEY FACTS PRODUCT & BUSINESS DEVELOPMENT IMMUNODIAGNOSTICS • FDA 510(k) clearance of the LIAISON® MUREX HIV Ab-Ag HT and the LIAISON® MUREX Control HIV Ab-Ag HT MOLECULAR DIAGNOSTICS TARGETED • Launch of a new Measles Virus Primer Pair in the U.S., expanding the growing portfolio of Analyte-
Slide 7: Managerial Outlook on Q2 and H1 2025 Revenues
MANAGERIAL OUTLOOK ON Q2 AND H1 2025 REVENUES Q2 2025 Group revenues (data in €/mln) H1 2025 Group revenues (data in €/mln) Data @CUR Data @CER Data @CUR Data @CER +2% +5% +5% +6% 317 619 626 300 306 300 589 589 7 3 7 14 5 3 5 44 14 91 92 COVID sales 42 41 84 84 41 50 103 105 49 47 49 100 100 Licens
Slide 8: Q2 and H1 2025 Revenues by Geography
Q2 AND H1 2025 REVENUES BY GEOGRAPHY Q2 2024 Q2 2025 Rest of the World Rest of the World 16% 15% North America North America Direct Direct 49% 49% Europe Direct Europe Direct 36% 35% H1 2024 H1 2025 Rest of the World Rest of the World 15% 14% North America North America Direct Direct 49% 51% Europe
Slide 9: Q2 and H1 2025 Profitability Profile
Q2 AND H1 2025 PROFITABILITY PROFILE (data in €/mln @ current exchange rates) 34% 35% 300 306 102 107 H1 2025 Adjusted1 EBITDA2 is better than last year by € 16 million, Net Revenues or by +8% (+10% at CER), with a higher incidence on revenues of about 100 bps at current and constant exchange rates.
Slide 10: FY 2025 Company Guidance
FY 2025 COMPANY GUIDANCE
Slide 11: FY'25 Guidance Confirmed
FY’25 GUIDANCE CONFIRMED FY’25 GUIDANCE (@CER 2024) Ex-COVID revenues: approx. +8%, approx. +7% including COVID revenues (equal to approx. 20 €/mln) Adjusted1 EBITDA2 Margin: approx. 34% 1 With reference to the Adjusted EBITDA, Adjusted EBIT and Adjusted Net Profit indicators, please refer to the ta
Slide 12: Financial Schemes
FINANCIAL SCHEMES
Slide 13: Income Statement
INCOME STATEMENT H1 Q2 Amounts in millions of euros 2024 2025 2024 2025 Net Revenues 589 619 300 306 Cost of sales (199) (213) (102) (105) Gross profit 390 406 198 201 66% 66% 66% 66% Sales and marketing expenses (141) (142) (71) (69) Research and development costs (43) (47) (21) (23) General and ad
Slide 14: Balance Sheet
BALANCE SHEET Amounts in millions of euros 12/31/2024 06/30/2025 Change Goodwill and intangibles assets 2,028 1,817 -212 Property, plant and equipment 271 256 -15 Other non-current assets 34 36 +1 Net working capital 346 356 +10 Other non-current liabilities (264) (249) +15 Net Invested Capital 2,41
Slide 15: Cash Flow Statement
CASH FLOW STATEMENT H1 Q2 Amounts in millions of euros 2024 2025 2024 2025 Cash and cash equivalents at the beginning of the period 280 344 308 365 Cash provided by operating activities 155 145 80 74 Cash provided/(used) in investing activities (11) (28) (50) (35) Cash provided/(used) in financing a
Slide 16: H1'25 Reconciliation to Consolidated Financial Statements
H1’25 RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS Amounts in millions of euros Gross Profit EBITDA EBIT Net Result Financial Statements Measures 406 204 138 99 % on Revenues 66% 33% 22% 16% Adjustments “One-off” costs related to non recurring events - 10 10 10 Depreciation of Luminex intangi
Slide 17: H1'24 Reconciliation to Consolidated Financial Statements
H1’24 RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS Amounts in millions of euros Gross Profit EBITDA EBIT Net Result Financial Statements Measures 390 196 132 96 % on Revenues 66% 33% 22% 16% Adjustments “One-off” costs related to the integration and restructuring of Luminex - 2 2 2 Depreciati
Slide 18: }) Diasorin
}) Diasorin